This CEO is working on a drug to slow Alzheimer's – Meet Cuong Do, CEO, Bioviepharm - $BIVI

Guest Name: Cuong Do


Title: President & CEO


Website: https://bioviepharma.com/


Ticker: BIVI


Bio:


Cuong Do


President & Chief Executive Officer​


Cuong Do, MBA, is the President and Chief Executive Officer of
BioVie Inc., a clinical-stage company developing innovative drug
therapies for the treatment of neurological and neurodegenerative
disorders and advanced liver disease. Do is a highly experienced
life sciences executive, who has served in various leadership
roles at multiple global enterprises and publicly owned companies
over the past 35 years. Prior to his appointment with BioVie, Do
was President of Samsung Global Strategy Group where he helped to
set the strategic direction for the company’s diverse business
portfolio, including the growth of its biologics businesses. He
was previously the Chief Strategy Officer for Merck, a leading US
pharmaceutical company on the Fortune 500 list, where he played a
key role in defining the company’s strategy, including its focus
on oncology and creating its leading position with the anti-PD-1
therapy, pembrolizumab (KEYTRUDA). Do also held leadership roles
in the technology space at Lenovo and Tyco Electronics, and was a
senior partner at McKinsey & Company, where he spent 17 years
helping to build the company’s healthcare, high tech and
corporate finance practices.





Do is an active entrepreneur who founded Callidus Biopharma (a
biotech company working in rare diseases that was acquired by
Amicus Therapeutics in 2013), Lysodel Therapeutics (a company
developing an innovative pharmaceutical product for obesity), and
M6P Therapeutics (a company developing gene and enzyme
replacement therapies for rare lysosomal storage disorders).





He is a founding member of Social Impact Partners, which is a
purpose-driven alliance of global experts and young change-makers
working to fight against Alzheimer’s Disease. Do also serves as a
member of multiple advisory boards to companies and academic
institutions, including Seneca Therapeutics, Stanford Medicine,
The Tuck School of Business at Dartmouth, Fulbright University
Vietnam, Ideal Semiconductors, ILiAD Biotechnologies and others.





Do is also a passionate philanthropist, particularly in autism
and education. He founded Profectum Foundation, which specializes
in providing training and education for professionals and parents
of children with autism or special needs. He also founded
Identifor, Inc. and the Identifor Foundation to help autistic
teenagers identify abilities and strengths to make the transition
to adulthood. He currently or formerly served on the boards of
Celebrate the Children (a school for children with special needs
in New Jersey), Autism Speaks and its Executive, Strategy,
Science and Family Services committees and Caring for Cambodia (a
non-profit working to educate 7,000+ K-12 students in Siem Reap,
Cambodia).





He holds a BA from Dartmouth College, and an MBA from the Tuck
School of Business at Dartmouth.